全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

苏云金杆菌对斯氏按蚊Hor株幼虫杀伤效果的分析

, PP. 1031-1034

Keywords: 苏云金芽孢杆菌以色列亚种,斯氏按蚊,杀伤效果,生物测定,蚊虫密度

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的检测苏云金杆菌以色列亚种(Bti)对斯氏按蚊Hor株四龄幼虫的杀灭效果及作用特点,为合理使用Bti进行蚊虫防治提供参考标准和理论依据。方法首先采用Probitanalysis生物测定的方法研究Bti剂量与斯氏按蚊幼虫累计死亡率的关系,通过线性回归分析获得相关公式,计算半致死浓度(LC50)等重要参数,探讨Bti对斯氏按蚊的杀伤效果。然后利用半致死浓度的Bti处理不同密度的斯氏按蚊幼虫,分析按蚊幼虫密度对Bti杀伤效果的影响。结果Bti对斯氏按蚊四龄幼虫的累计死亡率随作用时间和浓度的升高而增大,Bti的浓度对数值与累计死亡率P值呈较好的线性关系,根据所获得的公式计算出Bti作用12、24、48和72h后,半数致死浓度(LC50)分别为(1242±60)IU/L、(1112±45)IU/L、(1010±73)IU/L、(855±32)IU/L,95%致死浓度(LC95)分别为(4170±138)IU/L、(3746±444)IU/L、(3462±409)IU/L、(3080±464)IU/L。而且随着幼虫密度的增加,其累计死亡率显著降低。结论Bti株对斯氏按蚊四龄幼虫具有较好的杀伤效果,作用强、起效快,是一种较为理想的的灭蚊生物制剂;在Bti的使用剂量的确定上,应充分考虑蚊虫密度的因素,蚊虫密度越大所需Bti剂量应适当加大。

References

[1]  Bhatt S ,Gething P,Brady O, et al .The global distribution and burden of dengue. Nature, 2013.496(7446):504-507.
[2]  张复春.登革热:一个日益严重的全球性公共卫生问题.实用医学杂志,2011,27 (19):3459-3461.
[3]  Modi Y, Ogata S, Clements D,et al. Structure of the dengue virus envelope protein after membrane fusion.Nature.2004,427(6972):313-319
[4]  Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation,and fusion. Cell.2002,108(5):717-725.
[5]  Gregory D, Gromowski,,Alan DT. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain Ⅲ(ED3)of dengue 2 virus.Virology,2007,366(2):349-360.
[6]  Mota J, Acosta M, Argotte R, et al. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein .Vaccine. 2005,23(26):3469-3476.
[7]  Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology, 1990,174(20):450-458.
[8]  李敏,金侠 登革病毒疫苗研究现状与展望.生命的化学,2014,34(1):29-38.
[9]  Wright PJ,Cauchi MR, Ng ML, Definition of the carboxy termini of the three glycoproteins specified by dengue virus type 2. Virology, 1989,171(1):61-67.
[10]  Dejnirattisai W. Jumnainsong A, Qnsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science, 2010,328(5979):745-748.
[11]  Belramello M, Williams K, Simmons C, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell host microbe,2010.8(3):271-283.
[12]  Allison SL, Stadler K, Mandel CW, et al. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Vriol.1995, 69(9):5816-5820.
[13]  Raviprakash K, Porter KR, Kochel TJ, et al. Dengue virus type l DNA vaccine induces protective immune responses in rhesus macaques. J Gen Viro1, 2000, 81(7):1659-1667.
[14]  Kochel TJ, Raviprakash K, Hayes CG, et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine.2000, 18(27):3166-3173.
[15]  Raviprakash K, Kochel TJ, Ewing D, et al. Immunogenicity of dengue virus type .1 DNA vaccines expressing truncated and full length envelope protein.Vaccine.2000, 18(22):2416-2434.
[16]  Kochel T, Wu SJ, Raviprakash K et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine, 1997, 15(5):547-552.
[17]  Konishi E, Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine, 2002, 20(7):1058-1067.
[18]  Fonseca BA, Pincus S, Shope RE, et al. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 1994, 12(3):279-285.
[19]  Osorio JE, Huang CY, Kinney RM, et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever [J].Vaccine,2011,29(42):7251-7260.
[20]  Li XF, Deng YQ, Yang HQ, et al. A chimeric dengue virus vaccine using Japanese encephalitis vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice or nonhuman primates. J Virol,2013,87(24):13694-13705.
[21]  Brewoo J, Kinney R, Powell T, et al. Immunogenicity and efficacy of chimeric dengue vaccine(DENVax) formulation in interferon-deficient AG129 mice.Vaccine,2011,30(8):1513-1520.
[22]  Liu W Q, Jiang H N, Zhou J M, et al. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties[J].Virus Genes,2010,40(1):53-59.
[23]  Timofee AV, Butenko VM, Stephenson JR. Genetic vaccination of mice with plamids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes.2004,28(1):85-97.
[24]  Chalfie M, Tu Y, Euskirchen G, et al. Green fluorescent protein as a marker for gene expression .Science, 1994, 263(5148):802-805.
[25]  Gerdes HH, Kaether C. Green fluorescent applications: in cell biology. FEBS Lett, 1996, 389(1):44-47.
[26]  Scalesa SJ, Pepperkok R , KreisTE .Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPⅡand COPⅠ.Cell, 1997, 90(6):1137-1148.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133